Felty's syndrome. Risks and benefits of treatment with haemopoietic growth factors

BioDrugs

Volumn 7, Issue 5, 1997, Pages 356-365

  Pixley, John S ^a,b   Patchin, Gary M ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

DRUG COST; FELTY SYNDROME; HUMAN; LEUKOCYTE ACTIVATION; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SPLENECTOMY;

EID: 0030810946     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707050-00003     Document Type: Review

References (52)

1. Pinals RS. Felty's syndrome. In: Kelly WN, Harris ED Jr, Reddy S, et al., editors. Textbook of rheumatology. 3rd ed. Philadelphia: W. B. Saunders Company, 1989: 924-30
2. Ruderman M, Miller LM, Pinals RS. Clinical and serologic observations on 27 patients with Felty's syndrome. Arthritis Rheum 1968; 11: 377-84
3. Saway PA, Frasthofer EF, Barton JC. Prevalence of granular lymphocyte proliferation in patients with rheumatoid arthritis and neutropenia. Am J Med 1989; 86: 303-7
4. Van Der Veen JPW, Hack CE, Engelfriet CP, et al. Chronic idiopathic and secondary neutropenia: clinical and serological investigations. Br J Haematol 1986; 63: 161-71
5. Dale DC. Neutrophil disorders: benign, quantitative abnormalities of neutrophils. In: Williams WJ, Beutler E, Erslev AJ, et al., editors. Hematology. 4th ed. New York: McGraw-Hill Publishing Company, 1990: 807-16
6. Breedveld FC, Fibbe WF, Hermans J, et al. Factors influencing the incidence of infections in Felty's syndrome. Arch Intern Med 1987; 147: 915-20
7. Shastri KA, Logue GL. Autoimmune neutropenia. Blood 1993; 81: 1984-95
8. Joyce RA, Boggs DR, Chervenick PA. Neutrophil kinetics in Felty's syndrome. Am J Immunol 1980; 69: 695-702
9. Bagby GC Jr, Gabourel JD. Neutropenia in three patients with rheumatic disorders: suppression of granulopoiesis by cortisol-sensitive thymus- depended lymphocytes. J Clin Invest 1979; 64: 72-82
10. Slavin S, Liang MH. Cell mediated autoimmune granulocytopenia in a case of Felty's syndrome. J Rheum Dis 1980; 39: 399-402
11. Abdou NI. Heterogencity of bone marrow-directed immune mechanisms in the pathogenesis of neutropenia of Felty's syndrome. Arthritis Rheum 1983; 26: 947-53
12. Goldberg LS, Bacon PA, Bucknall RC, et al. Inhibition of human bone marrow-granulocyte precursors by serum from patients with Felty's syndrome. J Rheumatol 1980; 7: 275-8
13. Kuijpers TW, de Haas M, de Groot CJ, et al. The use of rh-G-CSF in chronic autoimmune neutropenia: reversal of autoimmune phenomena, a case history. Br J Haematol 1996; 94: 464-9
14. Sienknecht CW, Urowitz MB, Pruzanski W, et al. Felty's syndrome: clinical and serological analysis of 34 cases. Ann Rheum Dis 1977; 36: 500-7
15. Thorne C, Urowitz MB. Long-term outcome in Felty's syndrome. Ann Rheum Dis 1982; 41: 486-9
16. Louie SG, Jung B. Clinical effects of biologic response modifiers. Am J Hosp Pharm 1993; 50 Suppl. 3: 10-8
17. Metcalf D. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science 1991; 254: 529-33
18. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors: biological and clinical applications. N Engl J Med 1989; 321: 1449-59
19. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyle-macrophage colony-stimulating factor [first of two parts]. N Engl J Med 1992; 327: 28-35
20. Sahai J, Louie SG. Overview of the immune and hematopoietic system. Am J Hosp Pharm 1993; 50 Suppl. 3: 4-9
21. Hillman RS. Hemalopoielic agents: growth factors, mineral, and vitamins. In: Goodman's and Gilman's the pharmacological basis of therapeutics. New York: Pergamon, 1940: 1277-82
22. McEvoy GK, editor. Sargramostim. In: AHFS 96 drug information. Bethesda (MD): American Society of Health-System Pharmacists, Inc., 1996: 1056-65
23. Nemunaitis J. Granulocyte-macrophage-colony-stimulating factor: a review from preclinical development to clinical application. Transfusion 1993; 33: 70-83
24. Grant SM, Heel RC. Recombinant granulocyte-macrophage colony- stimulating factor (rGM-CSF): a review of its pharmacological properties and prospective role in the management of myclosuppression. Drugs 1992; 43: 516-60
25. Hazenberg BPC, Van Leeuwen MA, Van Rijswijk MH, et al. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony stimulating factor: simultaneous induction of interleukin-6 release and flare-up of the arthritis [letter]. Blood 1989; 74: 2769-70
26. Gabrilove JL. Introduction and overview of hematopoietic growth factors. Semin Hematol 1989; 26: 1-4
27. Filgrastim. In: McEvoy GK, editor. AHFS 96 drug information. Bethesda (MD): American Society of Health-System Pharmacists, Inc., 1996; 1048-56
28. Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy. Drugs 1994; 48: 731-60
29. Yasuda M, Kihara T, Wada T, et al. Granulocyte colony-stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty's syndrome patient. Arthritis Rheum 1994; 37: 145-6
30. Vidarsson B, Geirsson AJ, Onundarson PT. Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. Am J Med 1995; 98: 589-96
31. Farhey YD, Herman JH. Vasculitis complicating granulocyte colony simulating factor treatment of leukopenia and infection in Felty's syndrome. J Rheumatol 1995; 22: 1179-82
32. Park JW, Mehrotra B, Barnett BO, et al. The Sweet syndrome during therapy with granulocyte colony-stimulating factor. Ann Int Med 1992; 116: 996-8
33. Joseph G, Neustadt DH, Hamm J, et al. GM-CSF in the treatment of Felty syndrome. Am J Hematol 1991; 37: 55-6
34. Kaiser U, Klausmann M, Richter G, et al. GM-CSF versus G-CSF in the treatment of infectious complication in Felty's syndrome: a case report. Ann Hematol 1992; 64: 205-6
35. Nielsen H, Mejer J. Remission of neutropenia in a case of Felty's syndrome by rhG-CSF. Scand J Rheumatol 1992; 21: 305-7
36. Bhalla K, Ross R, Jeter E, et al. G-CSF improves granulocytopenia in Felty's syndrome without flare-up of arthritis. Am J Hematol 1993; 42: 230-1
37. Fraser DD, Sartiano GP, Buller TW, et al. Neulropenia of Felty's syndrome successfully treated with granulocyte colony stimulating factor. J Rheumatol 1993; 20: 1447-8
38. Marfeuille M, Clerc D, Mariette X. Successful treatment of agranulocytosis and sepsis with granulocyte colony stimulating factor in a case of Felty's syndrome. J Rheumatol 1995; 22: 1803-4
39. Yoshoika K. Combined therapy of G-CSF and prednisolone for neutropenia in a patient with Felty's syndrome. Am J Hematol 1995; 48: 130-42
40. Wagner DR, Combe C, Gresser U. GM-CSF and G-CSF in Felty's syndrome. Clin Invest 1993; 71: 168-71
41. Hoshina Y, Moriuchi J, Nakamura Y, et al. CD4+ T cell-mediated leukopenia of Felty's syndrome successfully treated with granulocyte-colony-stimulating factor and methotrexate. Arthritis Rreum 1994; 37: 298-9
42. Choi MFV, Mant MJ, Turner AR, et al. Successful reversal of neutropenia in Felty's syndrome with recombinant granulocyte colony stimulating factor. Br J Haematol 1994; 86: 663-4
43. Fohlman J, Hoglund M, Bergmann S. Successful treatment of chronic wound infection in neutropenia and rheumatoid arthritis with filgrastim (rhG-GSF). Ann Hematol 1994; 69: 153-6
44. Krishnaswamy G, Odem C, Chi DS, et al. Resolution of the neutropenia of Felty's syndrome by long term administration of recombinant granulocyte colony stimulating factor. J Rheumatol 1996; 23: 763-5
45. Wandt H, Seifert M, Falge C, et al. Long-term correction of neutropenia in Felty's syndrome with granulocyte colony-stimulating factor. Ann Hematol 1993; 66: 265-6
46. Markusse HM, Breedveld FC, Fibbe WE, et al. Granulocyte-macrophage colony-stimulating factor treatment of neutropenia associated with Felty's syndrome [letter]. Arthritis Rheum 1990; 33: 1865-6
47. Pixley JS, Yoneda KY, Manalo PB. Sequential administration of cyclophosphamide and granulocyte-colony stimulating factor relieves impaired myeloid maturation in Felty's syndrome. Am J Hematol 1993; 43: 304-6
48. Choi V, Mant M, Aaron S. Treatment of refractory Felty's syndrome with G-CSF and cyclophosphamide. Arthritis Rheum 1992; 32 Suppl.: 340
49. Maniscalso LA. Drug topics red book. July 1996 Update. Montvale (NJ): Medical Economics Company, Inc., 1996
50. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993; 85: 488-93
51. Glaspy JA, Jakway J. Cost considerations in therapy with myeloid growth factors. Am J Hosp Pharm 1993; 50 Suppl. 3: 19-26
52. Crawford J, Glaspy J. G-CSF for fever and neutropenia induced by chemotherapy. N Engl J Med 1992; 326: 270